Inhibition of Colonic Motility and Defecation by RS-127445 Suggests an Involvement of the 5-HT2B Receptor in Rodent Large Bowel Physiology

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2009 Apr 18

PMID 19371340

Citations 11

Authors

A K Bassil

C M Taylor

V J N Bolton

K M Gray

J D Brown

L Cutler

S G Summerfield

G Bruton

W J Winchester

K Lee

G J Sanger

Affiliations

Soon will be listed here.

Abstract

Background: 5-HT(2B) receptors are localized within the myenteric nervous system, but their functions on motor/sensory neurons are unclear. To explore the role of these receptors, we further characterized the 5-HT(2B) receptor antagonist RS-127445 and studied its effects on peristalsis and defecation.

Experimental Approach: Although reported as a selective 5-HT(2B) receptor antagonist, any interactions of RS-127445 with 5-HT(4) receptors are unknown; this was examined using the recombinant receptor and Biomolecular Interaction Detection technology. Mouse isolated colon was mounted in tissue baths for isometric recording of neuronal contractions evoked by electrical field stimulation (EFS), or under an intraluminal pressure gradient to induce peristalsis; the effects of RS-127445 on EFS-induced and on peristaltic contractions were measured. Faecal output of rats in grid-bottom cages was measured over 3 h following i.p. RS-127445 and separately, validation of the effective doses was achieved by determining the free, unbound fraction of RS-127445 in blood and brain.

Key Results: RS-127445 (up to 1 micromol x L(-1)) did not interact with the 5-HT(4) receptor. RS-127445 (0.001-1 micromol x L(-1)) did not affect EFS-induced contractions of the colon, although at 10 micromol x L(-1) the contractions were reduced (to 36 +/- 8% of control, n= 4). RS-127445 (0.1-10 micromol x L(-1)) concentration-dependently reduced peristaltic frequency (n= 4). RS-127445 (1-30 mg x kg(-1)), dose-dependently reduced faecal output, reaching significance at 10 and 30 mg x kg(-1) (n= 6-11). In blood and brain, >98% of RS-127445 was protein-bound.

Conclusions And Implications: High-protein binding of RS-127445 indicates that relatively high doses are required for efficacy. The results suggest that 5-HT(2B) receptors tonically regulate colonic motility.

Citing Articles

Serotoninergic Mechanisms of Action in the Relaxant Properties of Saccharomyces boulardii CNCM I-745 on the Intestine.

Girard P, Verleye M, Castagne V Dig Dis Sci. 2024; 70(1):191-202.

PMID: 39661276 PMC: 11761163. DOI: 10.1007/s10620-024-08786-y.

Serotonin receptor 2B induces visceral hyperalgesia in rat model and patients with diarrhea-predominant irritable bowel syndrome.

Li Z, Mao Y, Hua Q, Sun Y, Wang H, Ye X World J Gastroenterol. 2024; 30(10):1431-1449.

PMID: 38596485 PMC: 11000090. DOI: 10.3748/wjg.v30.i10.1431.

Serotonergic Control of Gastrointestinal Development, Motility, and Inflammation.

Najjar S, Hung L, Margolis K Compr Physiol. 2023; 13(3):4851-4868.

PMID: 37358510 PMC: 10373054. DOI: 10.1002/cphy.c220024.

Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor.

Wang Q, Zhou Y, Huang J, Huang N Pharmaceuticals (Basel). 2021; 14(2).

PMID: 33498477 PMC: 7909583. DOI: 10.3390/ph14020076.

International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.

Barnes N, Ahern G, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S Pharmacol Rev. 2020; 73(1):310-520.

PMID: 33370241 PMC: 7770494. DOI: 10.1124/pr.118.015552.

References

Bonhaus D, Flippin L, Greenhouse R, Jaime S, Rocha C, Dawson M . RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharmacol. 1999; 127(5):1075-82. PMC: 1566110. DOI: 10.1038/sj.bjp.0702632. View

Bockaert J, Claeysen S, Compan V, Dumuis A . 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord. 2004; 3(1):39-51. DOI: 10.2174/1568007043482615. View

Summerfield S, Stevens A, Cutler L, del Carmen Osuna M, Hammond B, Tang S . Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther. 2005; 316(3):1282-90. DOI: 10.1124/jpet.105.092916. View

Talley N, Phillips S, Haddad A, Miller L, Twomey C, Zinsmeister A . GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci. 1990; 35(4):477-80. DOI: 10.1007/BF01536922. View

Beattie D, Smith J, Marquess D, Vickery R, Armstrong S, Pulido-Rios T . The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004; 143(5):549-60. PMC: 1575425. DOI: 10.1038/sj.bjp.0705929. View

Maroteaux L, Gershon M . Serotonin and the 5-HT(2B) receptor in the development of enteric neurons. J Neurosci. 2000; 20(1):294-305. PMC: 6774223. View

Baxter G, Murphy O, Blackburn T . Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol. 1994; 112(1):323-31. PMC: 1910288. DOI: 10.1111/j.1476-5381.1994.tb13072.x. View

Wardle K, Bingham S, Ellis E, Gaster L, Rushant B, Smith M . Selective and functional 5-hydroxytryptamine4 receptor antagonism by SB 207266. Br J Pharmacol. 1996; 118(3):665-70. PMC: 1909720. DOI: 10.1111/j.1476-5381.1996.tb15452.x. View

Cheng Y, Prusoff W . Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22(23):3099-108. DOI: 10.1016/0006-2952(73)90196-2. View

10.

Kalvass J, Maurer T . Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos. 2002; 23(8):327-38. DOI: 10.1002/bdd.325. View

11.

McCullough J, Armstrong S, Hegde S, Beattie D . The 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat. Pharmacol Res. 2006; 53(4):353-8. DOI: 10.1016/j.phrs.2006.01.003. View

12.

Gore S, Gilmore I, Haigh C, Brownless S, Stockdale H, Morris A . Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther. 1990; 4(2):139-44. DOI: 10.1111/j.1365-2036.1990.tb00458.x. View

13.

Borman R, Burleigh D . 5-HT1D and 5-HT2B receptors mediate contraction of smooth muscle in human small intestine. Ann N Y Acad Sci. 1997; 812:222-3. DOI: 10.1111/j.1749-6632.1997.tb48182.x. View

14.

Cunningham B, Li P, Schulz S, Lin B, Baird C, Gerstenmaier J . Label-free assays on the BIND system. J Biomol Screen. 2004; 9(6):481-90. DOI: 10.1177/1087057104267604. View

15.

Bassil A, Dass N, Murray C, Muir A, Sanger G . Prokineticin-2, motilin, ghrelin and metoclopramide: prokinetic utility in mouse stomach and colon. Eur J Pharmacol. 2005; 524(1-3):138-44. DOI: 10.1016/j.ejphar.2005.09.007. View

16.

Fang Y, Frutos A, Verklereen R . Label-free cell-based assays for GPCR screening. Comb Chem High Throughput Screen. 2008; 11(5):357-69. DOI: 10.2174/138620708784534789. View

17.

De Maeyer J, Lefebvre R, Schuurkes J . 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008; 20(2):99-112. DOI: 10.1111/j.1365-2982.2007.01059.x. View

18.

Borman R, Tilford N, Harmer D, Day N, Ellis E, Sheldrick R . 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol. 2002; 135(5):1144-51. PMC: 1573235. DOI: 10.1038/sj.bjp.0704571. View

19.

Beattie D, Smith J . Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377(3):181-203. DOI: 10.1007/s00210-008-0276-9. View

20.

Alexander S, Mathie A, Peters J . Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol. 2008; 153 Suppl 2:S1-209. PMC: 2275471. DOI: 10.1038/sj.bjp.0707746. View